BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26005970)

  • 1. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
    Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
    Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
    Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
    Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
    Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
    Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
    Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-cancer-related survival benefit is associated with partial nephrectomy.
    Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
    Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
    Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
    BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.
    Zini L; Capitanio U; Perrotte P; Jeldres C; Shariat SF; Arjane P; Widmer H; Montorsi F; Patard JJ; Karakiewicz PI
    Urology; 2009 Feb; 73(2):342-6. PubMed ID: 19041122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
    Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
    Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
    BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
    Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
    Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
    Culp SH; Karam JA; Wood CG
    Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
    Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.